| Old Articles: <Older 6711-6720 Newer> |
|---|
 |
The Motley Fool
September 23, 2010
Ryan McBride |
Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.   |
The Motley Fool
September 22, 2010
Seth Jayson |
Will Edwards Lifesciences Whiff on Revenues Next Quarter? Look here for a clue. |
The Motley Fool
September 22, 2010
Seth Jayson |
Will Endo Pharmaceuticals Holdings Whiff on Revenues Next Quarter? Is Endo Pharmaceuticals sending any warning signs? Take a look at its accounts receivable and days sales outstanding for a clue. |
The Motley Fool
September 22, 2010
Seth Jayson |
Will Ensign Group Fall Short Next Quarter? For the last fully reported fiscal quarter, Ensign Group's year-over-year revenue grew 19.5%, and its AR grew 35.7%. |
The Motley Fool
September 22, 2010
Brian Orelli |
A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead. |
The Motley Fool
September 22, 2010
Jordan DiPietro |
A Huge Victory for Novartis MS oral drug is approved. |
The Motley Fool
September 22, 2010
Seth Jayson |
Will Medicis Pharmaceutical Whiff on Revenues Next Quarter? Medicis Pharmaceutical's year-over-year revenue grew 23.2%, and its AR grew 40.5%. That's a yellow flag. |
The Motley Fool
September 22, 2010
Brian Orelli |
Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown. |
The Motley Fool
September 21, 2010
Brian Orelli |
Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out. |
The Motley Fool
September 21, 2010
Seth Jayson |
What You Need to Know About Margins at C.R. Bard Here's the current margin snapshot for C.R. Bard and some of its sector and industry peers and direct competitors. |
| <Older 6711-6720 Newer> Return to current articles. |
